404 related articles for article (PubMed ID: 37203412)
1. Mechanisms of N6‑methyladenosine modification in tumor development and potential therapeutic strategies (Review).
Pu X; Wu Y; Ji Q; Fu S; Zuo H; Chu L; Tang H; Wan M; Wang X; Xu M
Int J Oncol; 2023 Jun; 62(6):. PubMed ID: 37203412
[TBL] [Abstract][Full Text] [Related]
2. The potential role of m6A modifications on immune cells and immunotherapy.
Gan L; Zhao Y; Fu Y; Chen Q
Biomed Pharmacother; 2023 Apr; 160():114343. PubMed ID: 36758318
[TBL] [Abstract][Full Text] [Related]
3. Ferroptosis in the tumor microenvironment: perspectives for immunotherapy.
Xu H; Ye D; Ren M; Zhang H; Bi F
Trends Mol Med; 2021 Sep; 27(9):856-867. PubMed ID: 34312075
[TBL] [Abstract][Full Text] [Related]
4. Ferroptosis: Promising approach for cancer and cancer immunotherapy.
Zheng S; Guan XY
Cancer Lett; 2023 May; 561():216152. PubMed ID: 37023938
[TBL] [Abstract][Full Text] [Related]
5. The N6-methyladenosine modification enhances ferroptosis resistance through inhibiting SLC7A11 mRNA deadenylation in hepatoblastoma.
Liu L; He J; Sun G; Huang N; Bian Z; Xu C; Zhang Y; Cui Z; Xu W; Sun F; Zhuang C; Man Q; Gu S
Clin Transl Med; 2022 May; 12(5):e778. PubMed ID: 35522946
[TBL] [Abstract][Full Text] [Related]
6. The Potential Value of m6A RNA Methylation in the Development of Cancers Focus on Malignant Glioma.
Chen F; Xie X; Chao M; Cao H; Wang L
Front Immunol; 2022; 13():917153. PubMed ID: 35711459
[TBL] [Abstract][Full Text] [Related]
7. Ferroptosis in cancer: From molecular mechanisms to therapeutic strategies.
Zhou Q; Meng Y; Li D; Yao L; Le J; Liu Y; Sun Y; Zeng F; Chen X; Deng G
Signal Transduct Target Ther; 2024 Mar; 9(1):55. PubMed ID: 38453898
[TBL] [Abstract][Full Text] [Related]
8. Targeting the RNA m
Li X; Ma S; Deng Y; Yi P; Yu J
Mol Cancer; 2022 Mar; 21(1):76. PubMed ID: 35296338
[TBL] [Abstract][Full Text] [Related]
9. N6-Methyladenosine RNA Modification in the Tumor Immune Microenvironment: Novel Implications for Immunotherapy.
Guo L; Yang H; Zhou C; Shi Y; Huang L; Zhang J
Front Immunol; 2021; 12():773570. PubMed ID: 34956201
[TBL] [Abstract][Full Text] [Related]
10. The interplay between m6A modification and non-coding RNA in cancer stemness modulation: mechanisms, signaling pathways, and clinical implications.
Qin S; Mao Y; Wang H; Duan Y; Zhao L
Int J Biol Sci; 2021; 17(11):2718-2736. PubMed ID: 34345203
[TBL] [Abstract][Full Text] [Related]
11. Crosstalk between N6-methyladenosine (m6A) modification and noncoding RNA in tumor microenvironment.
Wang D; Han Y; Peng L; Huang T; He X; Wang J; Ou C
Int J Biol Sci; 2023; 19(7):2198-2219. PubMed ID: 37151887
[TBL] [Abstract][Full Text] [Related]
12. Roles and therapeutic implications of m6A modification in cancer immunotherapy.
Pan J; Huang T; Deng Z; Zou C
Front Immunol; 2023; 14():1132601. PubMed ID: 36960074
[TBL] [Abstract][Full Text] [Related]
13. Novel insights into the interplay between m6A modification and programmed cell death in cancer.
Chen J; Ye M; Bai J; Hu C; Lu F; Gu D; Yu P; Tang Q
Int J Biol Sci; 2023; 19(6):1748-1763. PubMed ID: 37063421
[TBL] [Abstract][Full Text] [Related]
14. Detection of N6‑methyladenosine modification residues (Review).
Zhu W; Wang JZ; Xu Z; Cao M; Hu Q; Pan C; Guo M; Wei JF; Yang H
Int J Mol Med; 2019 Jun; 43(6):2267-2278. PubMed ID: 31017262
[TBL] [Abstract][Full Text] [Related]
15. The roles of ferroptosis in cancer: Tumor suppression, tumor microenvironment, and therapeutic interventions.
Lei G; Zhuang L; Gan B
Cancer Cell; 2024 Apr; 42(4):513-534. PubMed ID: 38593779
[TBL] [Abstract][Full Text] [Related]
16. FTO in cancer: functions, molecular mechanisms, and therapeutic implications.
Li Y; Su R; Deng X; Chen Y; Chen J
Trends Cancer; 2022 Jul; 8(7):598-614. PubMed ID: 35346615
[TBL] [Abstract][Full Text] [Related]
17. Characterization of m6A methylation modifications and tumor microenvironment infiltration in thyroid cancer.
Ji FH; Yang Z; Sun C; Lowe S; Qiu XG
Clin Transl Oncol; 2023 Jan; 25(1):269-282. PubMed ID: 36163443
[TBL] [Abstract][Full Text] [Related]
18. Diabetic Ferroptosis and Pancreatic Cancer: Foe or Friend?
Li L; Yu XJ; Gao L; Cheng L; Sun B; Wang G
Antioxid Redox Signal; 2022 Dec; 37(16-18):1206-1221. PubMed ID: 35996983
[No Abstract] [Full Text] [Related]
19. RNA m6A methylation regulators in endometrial cancer (Review).
Shen S; Guo J; Lv N; Chen Q; Tong J
Int J Oncol; 2022 Dec; 61(6):. PubMed ID: 36321774
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive Analysis of m6A RNA Methylation Regulators and the Immune Microenvironment to Aid Immunotherapy in Pancreatic Cancer.
Guo Y; Wang R; Li J; Song Y; Min J; Zhao T; Hua L; Shi J; Zhang C; Ma P; Yang C; Zhu L; Gan D; Li S; Liu X; Su H
Front Immunol; 2021; 12():769425. PubMed ID: 34804059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
